Key result
Biodegradable polymer sirolimus-eluting stents reduced target lesion failure at 1 year compared to durable polymer everolimus-eluting stents in STEMI patients.
Why the study?
Does a biodegradable polymer sirolimus-eluting stent reduce target lesion failure compared to a durable polymer everolimus-eluting stent in patients with acute STEMI?
RCT (n=407)
Single-blind
Stratified according to the presence or absence of STEMI
Yes
Does a biodegradable polymer sirolimus-eluting stent reduce target lesion failure compared to a durable polymer everolimus-eluting stent in patients with acute STEMI?
Answers are grounded in this paper and cite their sources.
In STEMI patients, an ultrathin strut biodegradable polymer sirolimus-eluting stent was associated with a significantly lower rate of target lesion failure at one year compared to a durable polymer everolimus-eluting stent.
AIMS: Our aim was to compare the safety and efficacy of a novel, ultrathin strut, biodegradable polymer sirolimus-eluting stent (BP-SES) with a thin strut, durable polymer everolimus-eluting stent (DP-EES) in a pre-specified subgroup of patients with acute ST-segment elevation myocardial infarction (STEMI) enrolled in the BIOSCIENCE trial. METHODS AND RESULTS: The BIOSCIENCE trial is an investigator-initiated, single-blind, multicentre, randomised non-inferiority trial (NCT01443104). Randomisation was stratified according to the presence or absence of STEMI. The primary endpoint, target lesion failure (TLF), is a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularisation within 12 months. Between February 2012 and May 2013, 407 STEMI patients were randomly assigned to treatment with BP-SES or DP-EES. At one year, TLF occurred in seven (3.4%) patients treated with BP-SES and 17 (8.8%) patients treated with DP-EES (RR 0.38, 95% CI: 0.16-0.91, p=0.024). Rates of cardiac death were 1.5% in the BP-SES group and 4.7% in the DP-EES group (RR 0.31, 95% CI: 0.08-1.14, p=0.062); rates of target vessel myocardial infarction were 0.5% and 2.6% (RR 0.18, 95% CI: 0.02-1.57, p=0.082), respectively, and rates of clinically indicated target lesion revascularisation were 1.5% in the BP-SES group versus 2.1% in the DP-EES group (RR 0.69, 95% CI: 0.16-3.10, p=0.631). There was no difference in the risk of definite stent thrombosis. CONCLUSIONS: In this pre-specified subgroup analysis, BP-SES was associated with a lower rate of target lesion failure at one year compared to DP-EES in STEMI patients. These findings require confirmation in a dedicated STEMI trial.
No takes yet. Share an insight, caveat, or question.
Pilgrim et al. (2016) conducted an RCT in Acute ST-segment elevation myocardial infarction (STEMI) (n=407). Biodegradable polymer sirolimus-eluting stent (BP-SES) vs. Durable polymer everolimus-eluting stent (DP-EES) was evaluated on Target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularisation within 12 months (RR 0.38, 95% CI 0.16-0.91, p=0.024). Biodegradable polymer sirolimus-eluting stents reduced target lesion failure at 1 year compared to durable polymer everolimus-eluting stents in STEMI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: